Université Libre De Bruxelles

Unibioscreen S.a.

Universitè Catholique De Louvain

Universitéde Liége

Facultés Universitaires Notre-Dame De La Paix

Robert Kiss

Eric Van Quaquebeke

Francis Darro

Jean-Claude Braekman

Gentiane Simon

Pierre Guissou

Odile Germaine Nacoulma

Janique Dewelle

Didier Cataldo

Didier Serteyn

Olivier Feron

Philippe Neven

Jacques Delarge

Bernard Masereel

Isabelle Camby

Patrick Henriet

Florence Lefranc

Pierre Courtoy

Jérôme Tuti

Laurent Van Den Hove

Veronique Mathieu

Natacha Rocks

Véronique Emmanuelle Julie Mathieu

Céline Anne Marie Michelle Meinguet

Celine Bruyere

Johan Wouters

Jeremy Reniers

Carole Lamy

Nicolas Vandelaer

Gabrielle Chataigne

Joelle Leclercq

Olivier Riant

Joëlle Leclercq

Novel phenazine derivatives of formula (I) are disclosed. In particular, substituted 2,3-dihydro-1H-benzo[a]pyrano[2,3-c]phenazines are disclosed. The compounds can be used as anti-angiogenic and/or anti-tumor agents.

Substituted 2,3-dihydro-1H-benzo[a]pyrano[2,3-c]phenazines as anti-angiogenic and anti-cancer agents

The invention provides novel beta-carboline derivatives of formulae (Ia) and (Ib) useful in the treatment of proliferative disorders including cancer, intermediates used in their preparation, processes for preparing the same and uses thereof. 

Beta carboline derivatives useful in the treatment of proliferative disorders

The present invention relates to the medical field. In a first aspect the present invention relates to novel water soluble cyclodextrin-curcumin complexes having a pharmacological activity, in particular an anti-tumor and/or anti-inflammatory activity, and improved physico-chemical properties. In a second aspect, the present invention relates to a method for preparation of said water soluble curcumin derivatives. The invention further relates in a third aspect to a pharmaceutical composition comprising an effective amount of said water soluble curcumin derivatives. In a fourth aspect, the present invention concerns the use of said water soluble cucumin derivatives as a medicament and the use of said water soluble curcumin derivatives for the preparation of a medicament for the treatment of cancer and inflammatory diseases. In a fifth aspect, the present invention relates to the use of a pharmaceutical composition comprising said water soluble curcumin derivatives in the treatment of cancer and inflammatory diseases and to a new pharmaceutical composition comprising said water soluble curcumin derivatives.

Water soluble curcumin compositions for use in anti-cancer and anti-inflammatory therapy

Compounds and pharmaceutical compositions which include 2&#x2033; oxo-voruscharin and derivatives are disclosed. The compounds and pharmaceutical compositions are useful in methods of treating cancer, particularly pancreatic cancer.

2&#x2033; oxo-voruscharin and derivatives thereof

The present invention relates to an RNAi molecule suitable for reducing the expression of galectin-1 containing any of the sequences of SEQ ID NOs: 1-33, and preferably the sequences of SEQ ID NO: 2, 3, or 4, and to the use thereof as a medicament, or for the manufacture of a medicament for treating and/or for delaying the progression of cancer, preferably glioma, pancreatic cancer, head and neck cancer, melanoma, non-small-cell lung cancer and non-Hodgkin's lymphoma. The present invention also relates to compositions and methods for treating and for delaying the progression of cancer, preferably glioma, pancreatic cancer, head and neck cancer, melanoma, non-small-cell lung cancer and non-Hodgkin's lymphoma, for reducing the migration of tumor cells, preferably cells of glioma, pancreatic cancer, head and neck cancer, melanoma, non-small-cell lung cancer and non-Hodgkin's lymphoma, and/or for enhancing the efficacy of cancer therapies for the treatment of cancer, preferably glioma, pancreatic cancer, head and neck cancer, melanoma, non-small-cell lung cancer and non-Hodgkin's lymphoma, selected from the group comprising chemotherapy, radiation therapy, immunotherapy, and/or gene therapy.

Use of a galectin-1-targeted RNAi-based approach for the treatment of cancer

The present invention is directed to azonafide derivatives obtained by reacting azonafide with aldehydes, acyl halides, thioacyl halides, monoisocyanates, isothiocyanates, sulfonyl halides, monohalogenoalkanes, monohalogenoalkenes or monohalogenoalkynes, and are useful as active ingredients of pharmaceutical compositions for the prevention and treatment of cell proliferative disorders, in particular several forms of cancer.

Azonafide derivatives, methods for their production and pharmaceutical compositions therefrom

2&#x2033; oxo-voruscharin compound and derivatives thereof are disclosed as well as pharmaceutical compositions which include 2&#x2033; oxo-voruscharin compound or derivatives thereof. The disclosed 2&#x2033; oxo-voruscharin compound and its derivatives are useful for cancer treatment. Methods of treating cancer using the disclosed compounds are also disclosed.

Growing community of inventors

Sint-Pieters-Leeuw, Belgium

Robert Kiss